Contact this trialFirst, we need to learn more about you.
GLP-1 RA
Semaglutide for Obesity
Recruiting4 awardsPhase 4
San Francisco, California
This trial will test whether semaglutide, a drug currently approved for weight loss, can also help reduce the burden of atrial fibrillation (AF). The study will last 52 weeks and will compare semaglutide to placebo. The primary outcome will be the change in AF burden for 2 weeks at the end of the study.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.